Abiopharma

🔍 LeMaitre George W (Director)

Company: LEMAITRE VASCULAR INC (LMAT)

Report Date: 2025-09-03

Detailed Transactions and Holdings:

• Sold 10,600 shares of Common Stock (Direct)
  Date: 2025-09-03 | Code: G | equity_swap_involved: 0 | shares_owned_after: 1,716,403.00 | transaction_form_type: 4
• Sold 10,600 shares of Common Stock (Direct)
  Date: 2025-09-03 | Code: G | equity_swap_involved: 0 | shares_owned_after: 1,705,803.00 | transaction_form_type: 4
• Acquired 2 shares of Dividend Equivalent Rights (Derivative)
  Date: 2025-09-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 48.52 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Acquired 3 shares of Dividend Equivalent Rights (Derivative)
  Date: 2025-09-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 52.98 | transaction_form_type: 4 | Footnotes: F2, F2, F2
• Acquired 6 shares of Dividend Equivalent Rights (Derivative)
  Date: 2025-09-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 73.96 | transaction_form_type: 4 | Footnotes: F3, F3, F3
• Acquired 6 shares of Dividend Equivalent Rights (Derivative)
  Date: 2025-09-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 73.25 | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Acquired 8 shares of Dividend Equivalent Rights (Derivative)
  Date: 2025-09-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 56.76 | transaction_form_type: 4 | Footnotes: F5, F5, F5
• Acquired 9 shares of Dividend Equivalent Rights (Derivative)
  Date: 2025-09-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 59.98 | transaction_form_type: 4 | Footnotes: F6, F6, F6
• Acquired 10 shares of Dividend Equivalent Rights (Derivative)
  Date: 2025-09-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 34.25 | transaction_form_type: 4 | Footnotes: F7, F7, F7

Footnotes:

• F1: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/2/2020 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
• F2: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
• F3: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
• F4: These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
• F5: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
• F6: These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
• F7: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.